We present a rare case of dermatomyositis associated with nivolumab therapy for melanoma. Nivolumab is an immune checkpoint inhibitor that blocks the programmed death-1 (PD1) receptor and has a number of associated immunotherapy related adverse events. Although most are T-cell mediated, some are antibody mediated mimics of classical autoimmune diseases. We review the characteristics of other cases of anti-PD1 associated dermatomyositis and the recent literature to better understand how to classify and treat this challenging immunotherapy related adverse event.
|Original language||English (US)|
|Journal||Dermatology online journal|
|State||Published - Aug 2020|
- Immune checkpoint inhibitors
- Immunotherapy-related adverse events
- PD 1
ASJC Scopus subject areas